CHO Pharma, Inc.

Informe acción TPEX:6586

Capitalización de mercado: NT$11.7b

CHO Pharma Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chung-Yi Wu

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO2.2yrs
Participación del CEOn/a
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directiva2.9yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn Situation

We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn Rate

Dec 09
We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn Rate

CEO

Chung-Yi Wu

2.2yrs

Permanencia

Dr. Chung-Yi Wu serves as President at CHO Pharma, Inc. since March 2022 and serves as its General Manager & Director since 2022 and also serves as its Chief Executive Officer. He served as Executive Vice...


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Chung-Yi Wu
President2.3yrssin datossin datos
Ming-Hsing Tsai
Director2.3yrssin datossin datos
Pan-Chyr Yang
Member of Scientific Advisory Boardno datasin datossin datos
Chi-Huey Wong
Chairman of Scientific Advisory Boardno datasin datossin datos
Shaw T. Chen
Member of Scientific Advisory Boardno datasin datossin datos
Hsieng S. Lu
Member of Scientific Advisory Boardno datasin datossin datos
Chao-Long Chen
Chairmanno datasin datossin datos
Shuan-Ta Liu
Independent Director4.9yrssin datossin datos
Kuo-I Lin
Member of Scientific Advisory Board2.9yrssin datossin datos
Che Alex Ma
Member of Scientific Advisory Boardno datasin datossin datos
Mei-Shang Ho
Member of Scientific Advisory Board3.3yrssin datossin datos
Chung-Liang Chien
Independent Directorno datasin datossin datos

2.9yrs

Permanencia media

Junta con experiencia: La junta directiva de 6586 no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.